| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2004;110:1213-1218.)
© 2004 American Heart Association, Inc.
Original Articles |
From the Department of Cardiology, University Hospital, Basel, Switzerland.
Correspondence to M. Pfisterer, MD, FAHA, FESC, FACC, Principal Investigator TIME, Professor and Head, Department of Cardiology, University Hospital, CH-4031 Basel, Switzerland. E-mail pfisterer{at}email.ch
Received March 23, 2004; accepted May 20, 2004.
Background There are no prospective trial data on long-term outcomes in 80-year-old patients with chronic angina with regard to antiischemic therapy.
Methods and Results To assess long-term survival and quality of life (QoL) in patients from the Trial of Invasive versus Medical Therapy in the Elderly (TIME), all 276 1-year survivors (of a total 301 patients) were contacted after a median of 3.1 years (range, 1.1 to 5.9 years). At baseline, patients were 80±4 years old, 42% were women, and they were designated as being in angina class 3.2±0.7, despite their taking 2.5±0.7 antiischemic drugs. Patients were randomized to an invasive (n=153) or an optimized medical (n=148) strategy. Survival of invasive-strategy versus medical-strategy patients was 91.5% versus 95.9% after 6 months, 89.5% versus 93.9% after 1 year, and 70.6% versus 73.0% after 4.1 years (P=NS). Mortality was independently increased in patients
80 years of age, with prior heart failure, ejection fraction
0.45, and
2 comorbidities, and without revascularization within the first year. Revascularization within the first year improved survival in invasive-strategy (P=0.07) and medical-strategy (P<0.001) patients. The early benefit of both treatments in angina relief and QoL was maintained long term, but freedom from major events remained higher in invasive-strategy versus medical-strategy patients (39% versus 20%, P<0.0001).
Conclusions Long-term survival was similar for patients assigned to invasive and medical treatment. The benefits of both treatments in angina relief and improvement in QoL were maintained, but nonfatal events occurred more frequently in patients assigned to medical treatment. Irrespective of whether patients were catheterized initially or only after drug therapy failure, their survival rates were better if they were revascularized within the first year.
Key Words: aging angina survival drugs revascularization
This article has been cited by other articles:
![]() |
H. V. Anderson Drug-eluting stents life insurance with a better death benefit. J. Am. Coll. Cardiol., May 27, 2008; 51(21): 2025 - 2027. [Full Text] [PDF] |
||||
![]() |
G. Devlin, J. M. Gore, J. Elliott, N. Wijesinghe, K. A. Eagle, A. Avezum, W. Huang, D. Brieger, and for the GRACE Investigators Management and 6-month outcomes in elderly and very elderly patients with high-risk non-ST-elevation acute coronary syndromes: The Global Registry of Acute Coronary Events Eur. Heart J., May 2, 2008; 29(10): 1275 - 1282. [Abstract] [Full Text] [PDF] |
||||
![]() |
Stable angina who needs revascularisation? DTB, February 1, 2007; 45(2): 12 - 16. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Montalescot Glycoprotein IIb/IIIa Inhibitors in the Elderly: Fear of Age or Age of Fear? Circulation, November 7, 2006; 114(19): 2004 - 2006. [Full Text] [PDF] |
||||
![]() |
M. J. Radford Percutaneous Coronary Intervention "Dominates" Coronary Artery Bypass Graft Surgery for High-Risk Patients: Good News for Patients, a Challenge for Healthcare Planners Circulation, September 19, 2006; 114(12): 1229 - 1231. [Full Text] [PDF] |
||||
![]() |
K. T. Stroupe, D. A. Morrison, M. A. Hlatky, P. G. Barnett, L. Cao, C. Lyttle, D. M. Hynes, W. G. Henderson, and for the Investigators of Veterans Affairs Cooperat Cost-Effectiveness of Coronary Artery Bypass Grafts Versus Percutaneous Coronary Intervention for Revascularization of High-Risk Patients Circulation, September 19, 2006; 114(12): 1251 - 1257. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Kaehler, T. Meinertz, and C. W Hamm Coronary interventions in the elderly. Heart, August 1, 2006; 92(8): 1167 - 1171. [Full Text] [PDF] |
||||
![]() |
L Purek, K Laule-Kilian, A Christ, T Klima, M E Pfisterer, A P Perruchoud, and C Mueller Coronary artery disease and outcome in acute congestive heart failure Heart, May 1, 2006; 92(5): 598 - 602. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Gabriel Steg and D. Himbert Unmet medical needs and therapeutic opportunities in stable angina Eur. Heart J. Suppl., September 1, 2005; 7(suppl_H): H7 - H15. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. W. O'Neill, S. R. Dixon, and C. L. Grines The year in interventional cardiology J. Am. Coll. Cardiol., April 5, 2005; 45(7): 1117 - 1134. [Full Text] [PDF] |
||||
![]() |
Authors/Task Force Members, S. Silber, P. Albertsson, F. F. Aviles, P. G. Camici, A. Colombo, C. Hamm, E. Jorgensen, J. Marco, J.-E. Nordrehaug, et al. Guidelines for Percutaneous Coronary Interventions: The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology Eur. Heart J., April 2, 2005; 26(8): 804 - 847. [Full Text] [PDF] |
||||
![]() |
ADDITIONAL ARTICLES ABSTRACTED IN ACP JOURNAL CLUB Evid. Based Med., April 1, 2005; 10(2): 62 - 62. [Full Text] [PDF] |
||||
![]() |
P. O. Bonetti, C. Kaiser, M. J. Zellweger, L. Grize, P. Erne, R. A. Schoenenberger, M. E. Pfisterer, and TIME Investigators Long-Term Benefits and Limitations of Combined Antianginal Drug Therapy in Elderly Patients with Symptomatic Chronic Coronary Artery Disease Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2005; 10(1): 29 - 37. [Abstract] [PDF] |
||||
![]() |
J. P. Curtis and H. M. Krumholz Keeping the Patient in View: Defining the Appropriateness of Percutaneous Coronary Interventions Circulation, December 21, 2004; 110(25): 3746 - 3748. [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |